Coverage
-
April 13, 2015
Questcor Pharmaceuticals Inc. on Monday agreed to pay $38 million to end a consolidated securities class action alleging the company lies about the efficacy of its biggest moneymaker, multiple sclerosis drug Acthar.
2 other articles on this case.
View all »